Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects Who Have Peripheral Ischemic Ulcers of the Lower Extremity

NCT04267640 is registered in ClinicalTrials.gov with AnGes USA, Inc. as lead sponsor.

NCT NCT04267640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04267640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects Who Have Peripheral Ischemic Ulcers of the Lower Extremity
Lead sponsor
AnGes USA, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
January 30, 2020
Completion date
January 31, 2023
Enrollment
60 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

chronic limb threatening ischemia, ischaemic ulcer of lower leg due to atherosclerotic disease, ischemic ulcer of foot, peripheral artery disease